jakavi
novartis europharm limited - ruksolitinibas (fosfatas) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antinavikiniai vaistai - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi fluorouracilu ir folino suaugusių pacientų su polycythaemia vera, kurie yra atsparūs arba netoleruoja hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
locametz
novartis europharm limited - gozetotide - radionuklidų vaizdavimas - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatos navikai, kastracija-atsparus - terapiniai radiofarmaciniai preparatai - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
vigamox
sia novartis baltics - moksifloksacinas - akių lašai (tirpalas) - 5 mg/ml - moxifloxacin
miflonide breezhaler
sia novartis baltics - budezonidas - įkvepiamieji milteliai (kietosios kapsulės) - 400 µg; 200 µg - budesonide
tobrex
sia novartis baltics - tobramicinas - akių tepalas - 3 mg/ml; 3 mg/g - tobramycin
ciloxan
sia novartis baltics - ciprofloksacinas - akių lašai (tirpalas) - 3 mg/ml - ciprofloxacin
tevimbra
novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antinavikiniai vaistai - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.
focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - gripo vakcinos - a (h1n1v) 2009 viruso sukeltos gripo profilaktika. focetria turėtų būti naudojami laikantis oficialių rekomendacijų.
esb3 30 %, geriamieji milteliai
novartis animal health d.o.o. (slovėnija) - geriamieji milteliai - sulfaclozine sodium monohydrate - 30.0 g; excipient up to 100.0 g - naminiams paukščiams, sergantiems kokcidioze, sukelta jautrių virusui eimerijų (eimeria acervulina, e. maxima, e. necatrix, e. tenella ar e. brunetti), salmonelioze, sukleta salmonella gallinarum, bei pasterelioze, sukelta pasteurella multocida, gydyti.